Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Feedback from today's Meeting with Large Shareholders

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Jan 24, 2022 3:29pm

157 Views

Post# 34354738

RE:Feedback from today's Meeting with Large Shareholders

So what exactly then was the point of these meetings that could not have been accomplished with a phone call or better yet a news release to update everybody on what's going on? Instead we'll fly everybody out for a road trip. Doesn't sound all that environmentally friendly to me. Another case of do as I say not as I do.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo